These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 2955413)
21. Mutated epitopes of hepatitis B surface antigen fused to the core antigen of the virus induce antibodies that react with the native surface antigen. Shiau AL; Murray K J Med Virol; 1997 Mar; 51(3):159-66. PubMed ID: 9139078 [TBL] [Abstract][Full Text] [Related]
22. A new hamster model for adenoviral vaccination. Hjorth RN; Bonde GM; Pierzchala WA; Vernon SK; Wiener FP; Levner MH; Lubeck MD; Hung PP Arch Virol; 1988; 100(3-4):279-83. PubMed ID: 2840876 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. Ambriović A; Adam M; Monteil M; Paulin D; Eloit M Virology; 1997 Nov; 238(2):327-35. PubMed ID: 9400605 [TBL] [Abstract][Full Text] [Related]
24. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Mittal SK; Papp Z; Tikoo SK; Baca-Estrada ME; Yoo D; Benko M; Babiuk LA Virology; 1996 Aug; 222(2):299-309. PubMed ID: 8806514 [TBL] [Abstract][Full Text] [Related]
25. Immunological analysis of 140-kDa adenovirus-encoded DNA polymerase in adenovirus type 2-infected HeLa cells using antibodies raised against the protein expressed in Escherichia coli. Sasaguri Y; Sanford T; Aguirre P; Padmanabhan R Virology; 1987 Oct; 160(2):389-99. PubMed ID: 3310382 [TBL] [Abstract][Full Text] [Related]
26. Protective effect of a synthetic peptide comprising the complete preS2 region of the hepatitis B virus surface protein. Emini EA; Larson V; Eichberg J; Conard P; Garsky VM; Lee DR; Ellis RW; Miller WJ; Anderson CA; Gerety RJ J Med Virol; 1989 May; 28(1):7-12. PubMed ID: 2723618 [TBL] [Abstract][Full Text] [Related]
28. The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore. Guan R; Tay HH; Yap I; Smith R; Tan LH Trans R Soc Trop Med Hyg; 1990; 84(5):731-2. PubMed ID: 2148992 [No Abstract] [Full Text] [Related]
29. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. Poovorawan Y; Sanpavat S; Pongpunlert W; Chumdermpadetsuk S; Sentrakul P; Safary A JAMA; 1989 Jun; 261(22):3278-81. PubMed ID: 2523981 [TBL] [Abstract][Full Text] [Related]
30. Intradermal hepatitis B virus vaccination for low- or non-responded health-care workers. Yasumura S; Shimizu Y; Yasuyama T; Hiroki O; Okada K; Tsukishiro T; Tsuchida T; Higuchi K; Watanabe A Acta Med Okayama; 1991 Dec; 45(6):457-9. PubMed ID: 1838229 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children. Moyes C; Milne A N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799 [TBL] [Abstract][Full Text] [Related]
32. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. Gunn TR; Bosley A; Woodfield DG N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527 [TBL] [Abstract][Full Text] [Related]
33. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. Singh M; Cattaneo R; Billeter MA J Virol; 1999 Jun; 73(6):4823-8. PubMed ID: 10233943 [TBL] [Abstract][Full Text] [Related]
35. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Xiang ZQ; Yang Y; Wilson JM; Ertl HC Virology; 1996 May; 219(1):220-7. PubMed ID: 8623532 [TBL] [Abstract][Full Text] [Related]
36. [Construction of recombinant adeno-associated virus carrying hepatitis B surface antigen gene and preliminary study of the gene expression and function]. Hu GF; Wu XB; Yu SY; Dong XY; Chen Q; Hou YD Di Yi Jun Yi Da Xue Xue Bao; 2003 Jun; 23(6):553-6. PubMed ID: 12810373 [TBL] [Abstract][Full Text] [Related]
37. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Phillpotts RJ; O'brien L; Appleton RE; Carr S; Bennett A Vaccine; 2005 Feb; 23(13):1615-23. PubMed ID: 15694514 [TBL] [Abstract][Full Text] [Related]
39. [Results of an anti-hepatitis-B vaccination in a population at risk]. Stellato M; Carbi S; Tosolini S Boll Ist Sieroter Milan; 1989; 68(1):34-41. PubMed ID: 2535244 [TBL] [Abstract][Full Text] [Related]
40. Recombinant hepatitis B vaccine. Med Lett Drugs Ther; 1986 Dec; 28(728):118-9. PubMed ID: 2946924 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]